Using brain stimulation to treat apathy in Alzheimer's disease
Official title: Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)
Run by Sunnybrook Health Sciences Centre · NCT05561205 · Data updated 2026-11-12
This study is testing whether a brain stimulation treatment can help reduce feelings of apathy in people with Alzheimer's disease, including those who are taking a medication for it.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Sunnybrook Health Sciences Centre Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | February 9, 2023 |
| Main results expected | December 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | April 13, 2026 |
| Trial ID | NCT05561205 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals diagnosed with Alzheimer's disease who have experienced apathy for at least four weeks.
✕Probably not a fit
Patients currently experiencing a major depressive episode or those with certain neurological conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for apathy in individuals with Alzheimer's disease. Participants will include those receiving methylphenidate, a medication known to improve apathy, and those not on any medication. The study aims to assess the effectiveness of rTMS in alleviating symptoms of apathy, which is a common and debilitating condition in dementia. The trial will include individuals diagnosed with major neurocognitive disorders who have experienced apathy for at least four weeks.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life for patients with Alzheimer's disease by reducing apathy.
How similar studies have gone: Other studies have shown promise in using rTMS for various neurological conditions, suggesting potential for success in this novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * mild or major neurocognitive disorder OR mild behavioural impairment * Apathy for at least 4 weeks * Stable dose of medication (\>4 weeks) that may affect cognition or behaviour * Care partner who spends at least 10 hours a week with the subject Exclusion Criteria: * Current major depressive episode * Agitation, delusions, hallucination * Medical contraindications to rTMS * Currently taking an amphetamine product * Central nervous system abnormalities, Tourette's syndrome, or motor tics * Current participation in another clinical trial
Where it's running
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using a passive home sensor to find digital signs of brain energy changes from nicotinamide riboside
This project will try a contact-free home sensor to see if it can detect activity, sleep, and breathing changes related to nicotinamide riboside in people with mild cognitive impairment or mild Alzheimer's.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
Blood tests using plasma biomarkers to diagnose and track Alzheimer’s disease
A large, year-long study in Milan is testing whether blood markers can help diagnose Alzheimer’s and predict how it will progress in people with memory concerns.
-
Music for Pain and Dementia: Group Drumming for people with early dementia and their caregivers
This study tests whether group drumming can reduce pain and change brain activity in people with mild dementia or mild cognitive impairment and in their caregivers.
-
Fast-track screening to determine eligibility for anti-amyloid treatment using digital cognitive tests and blood biomarkers.
This project will test whether combining self‑administered digital cognitive tests with blood biomarker results can quickly identify patients referred for memory concerns who may qualify for anti‑amyloid disease‑modifying therapy.
-
Ultralow-dose amyloid PET with 18F‑Florbetapir or 18F‑Flutemetamol
This trial will try using a very small amount of an amyloid PET tracer with a high-sensitivity PET scanner to see if clear brain images can be made for people with Alzheimer’s, mild cognitive impairment, other dementias, and healthy volunteers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.